Compare · ARGX vs IMVT
ARGX vs IMVT
Side-by-side comparison of argenx SE (ARGX) and Immunovant Inc. (IMVT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and IMVT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 7.0x IMVT ($8.99B).
- Over the past year, ARGX is up 44.0% and IMVT is up 188.1% - IMVT leads by 144.2 points.
- ARGX has been more active in the news (11 items in the past 4 weeks vs 4 for IMVT).
- Both have 25 recent analyst ratings on file.
- Company
- argenx SE
- Immunovant Inc.
- Price
- -
- -
- Market cap
- $63.27B
- $8.99B
- 1M return
- +14.62%
- +8.50%
- 1Y return
- +43.97%
- +188.15%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2019
- News (4w)
- 11
- 4
- Recent ratings
- 25
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Immunovant Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Latest ARGX
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE
Latest IMVT
- Chief Operating Officer Gloria Melanie sold $134,953 worth of shares (3,056 units at $44.16), decreasing direct ownership by 1% to 219,301 units (SEC Form 4) (withholding tax)
- SEC Form 10-Q filed by Immunovant Inc.
- Immunovant Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
- Director Pande Atul exercised 1,500 shares at a strike of $8.43 and sold $59,700 worth of shares (1,500 units at $39.80) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Girao Tiago sold $263,015 worth of shares (6,798 units at $38.69), decreasing direct ownership by 3% to 240,798 units (SEC Form 4) (for withholding tax)
- Chief Technology Officer Stout Jay S sold $110,537 worth of shares (2,857 units at $38.69), decreasing direct ownership by 1% to 205,341 units (SEC Form 4) (for withholding tax)
- Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
- SEC Form DEFA14A filed by Immunovant Inc.
- SEC Form DEF 14A filed by Immunovant Inc.